June2016

News Hour: Former ICC World Twenty20 champion India missed a chance to wrest back the top position on the MRF Tyres ICC T20I Team Rankings despite defeating Zimbabwe by 2-1 in the three-match series in Harare...

News Hour: The International Cricket Council (ICC) today confirmed that following remedial work and a retest, the bowling action of Zimbabwe’s Brian Vitori has been found to be legal, and the left-arm fast bowler can now...

News Hour: Women Deliver, a global advocacy organization, awarded seed grants of US$5,000 each to 20 Young Leaders to support six-month projects aimed at advancing girls’ and women’s health, rights and wellbeing in their communities. Like...

News Hour: Novartis announced that it will present 33 scientific abstracts at the Annual European Congress of Rheumatology (EULAR 2016) in London, UK. This includes new long-term analyses suggesting Cosentyx® (secukinumab) may lead to higher responses...

News Hour: Novartis  announced data from a Phase III study showing a significant survival benefit for patients with BRAF V600E/K mutation-positive advanced melanoma when treated with the first-line combination of Tafinlar® (dabrafenib) + Mekinist® (trametinib) compared...

News Hour: Novartis announced positive first results from the global phase II 20120295 study, investigating the efficacy and safety of the fully human monoclonal antibody AMG 334 (erenumab) in chronic migraine prevention. The study evaluated AMG...

News Hour: Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, announced results from two key studies comparing its  biosimilar etanercept and rituximab candidates with the originator products – Enbrel® and MabThera® respectively. In both...

News Hour: Novartis  announced Phase III data from RESPONSE-2 showing that Jakavi®(ruxolitinib) helped patients with polycythemia vera (PV), who did not have an enlarged spleen and were resistant to or intolerant of hydroxyurea, achieve superior hematocrit...

News Hour: Novartis  announced data from the largest study of its kind confirming the long-term safety profile of Revolade (eltrombopag) in adults with chronic immune (idiopathic) thrombocytopenia (ITP), with data for up to 6 years in...

News Hour: Novartis announced  that it will further expand its long-standing partnership with Medicines for Malaria Venture (MMV). Novartis will lead the development of antimalarial compound KAF156 with scientific and financial support from MMV in collaboration...